News

Providence Brain and Cancer Experts Begin First-In-World Novel Brain Tumor Vaccine Research Trial

May 05, 2014

Fourteen months. That’s the median life expectancy of someone diagnosed with high-grade glioma, the most common primary brain tumor in adults, even with the current standard of treatment. Providence Cancer Center researchers and a Providence Brain and Spine Institute neurosurgeon believe immunotherapy might change that statistic. 

Outcomes promising in OX40 study at Providence Cancer Center

December 11, 2013

Portland-area researchers have scored promising results in the hottest field in cancer research today: Using the immune system to fight tumors. The results are a victory in an underdog story of achieving results without pharmaceutical company backing. 

Providence cancer drug trial wins FDA approval

April 11, 2011

Ipilimumab is the first drug shown to extend survival in patients with late-stage melanoma.